Terra Nova Asset Management LLC Invests $1.87 Million in Genmab A/S Sponsored ADR $GMAB

Key Points

• Terra Nova Asset Management bought a new stake of 60,600 Genmab ADR shares in Q4, valued at about $1.87 million, joining several other institutions that increased holdings during the quarter.
• Analysts show a mixed-to-positive view: the consensus rating is a “Moderate Buy” with an average price target of $39.36, while recent reports range from Strong Buy/Outperform to Equal Weight.
• Genmab recently reported an earnings miss (EPS $0.05 vs. $0.46 expected) though revenue matched estimates at $1.06 billion, and the stock trades near $25.82 with a 52‑week range of $17.24–$35.43 and a market cap of $16.59 billion.

Terra Nova Asset Management LLC bought a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 60,600 shares of the company's stock, valued at approximately $1,866,000.

Other large investors also recently added to or reduced their stakes in the company. DAVENPORT & Co LLC boosted its stake in Genmab A/S by 33.6% in the 4th quarter. DAVENPORT & Co LLC now owns 44,761 shares of the company's stock worth $1,379,000 after purchasing an additional 11,265 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Genmab A/S by 10.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 14,818 shares of the company's stock worth $490,000 after buying an additional 1,350 shares in the last quarter. Park Avenue Securities LLC boosted its position in shares of Genmab A/S by 6.3% during the fourth quarter. Park Avenue Securities LLC now owns 17,870 shares of the company's stock worth $550,000 after acquiring an additional 1,066 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Genmab A/S by 59.5% during the fourth quarter. GAMMA Investing LLC now owns 4,755 shares of the company's stock worth $146,000 after acquiring an additional 1,773 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in Genmab A/S by 23.5% during the third quarter. Caitong International Asset Management Co. Ltd now owns 7,172 shares of the company's stock valued at $220,000 after acquiring an additional 1,363 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GMAB has been the subject of several research reports. Truist Financial raised shares of Genmab A/S to a "strong-buy" rating in a report on Wednesday. Guggenheim cut their price objective on Genmab A/S from $45.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, February 23rd. Wolfe Research assumed coverage on Genmab A/S in a report on Friday. They issued an "outperform" rating and a $32.00 target price on the stock. Wells Fargo & Company assumed coverage on Genmab A/S in a research report on Monday, March 2nd. They issued an "overweight" rating and a $40.00 target price on the stock. Finally, Morgan Stanley assumed coverage on Genmab A/S in a report on Monday, February 16th. They set an "equal weight" rating and a $34.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $39.36.

Genmab A/S Price Performance

GMAB stock opened at $25.82 on Friday. Genmab A/S Sponsored ADR has a 52 week low of $17.24 and a 52 week high of $35.43. The firm has a market capitalization of $16.59 billion, a P/E ratio of 16.66, a price-to-earnings-growth ratio of 1.06 and a beta of 0.94. The company has a fifty day simple moving average of $29.40 and a two-hundred day simple moving average of $30.47. The company has a quick ratio of 2.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The business had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.06 billion. Analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company's work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab's portfolio includes products developed in collaboration with leading global pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.